Literature DB >> 34167511

Zoledronic acid and teriparatide have a complementary therapeutic effect on aseptic loosening in a rabbit model.

Peng Wang1, Guang-Qian Shang1, Shuai Xiang1, Hai-Ning Zhang1, Ying-Zhen Wang1, Hao Xu2.   

Abstract

BACKGROUND: Revisions are mainly caused by wear debris-induced aseptic loosening. How to effectively suppress debris-induced periprosthetic osteolysis has become an urgent problem. Both zoledronic acid and teriparatide can increase the bone mass around prostheses and increase the stability of prostheses. A hypothesis was proposed: the combination of the two drugs may have a better treatment effect than the use of either drug alone.
METHODS: We created a rabbit model to study the effect and mechanism of the combination of zoledronic acid and teriparatide in the treatment of aseptic loosening. Thirty-two adult male New Zealand white rabbits were selected and treated with TKA surgery, and a titanium rod prosthesis coated evenly with micrometre-sized titanium debris was implanted into the right femoral medullary cavity. All rabbits were randomized into four groups (control group = 8, zoledronic acid group = 8, teriparatide group = 8, and zoledronic acid + teriparatide group = 8). All the animals were sacrificed in the 12th week, and X-ray analyses, H&E staining, Goldner-Masson trichrome staining, von Kossa staining, and RT-PCR and Western blotting of the mRNA and protein of OCN, OPG, RANKL and TRAP5b in the interface membrane tissues around the prostheses were immediately carried out.
RESULTS: The results shown that both zoledronic acid and teriparatide could inhibit debris-induced peri-prosthetic osteolysis and promote new bone formation. Zoledronic acid was more capable of inhibiting osteoclast activation and peri-prosthetic osteolysis, while teriparatide was more capable of promoting osteoblast function and peri-prosthetic bone integration.
CONCLUSION: This research confirmed that the combination of zoledronic acid and teriparatide could prevent and treat aseptic loosening of the prosthesis more effectively. However, the safety of this combination and the feasibility of long-term application have not been ensured, and the clinical application requires further experiments and clinical research support.

Entities:  

Keywords:  Aseptic loosening; Osteoblast; Osteoclast; Teriparatide; Wear debris; Zoledronic acid

Mesh:

Substances:

Year:  2021        PMID: 34167511     DOI: 10.1186/s12891-021-04458-4

Source DB:  PubMed          Journal:  BMC Musculoskelet Disord        ISSN: 1471-2474            Impact factor:   2.362


  37 in total

Review 1.  Aseptic loosening, not only a question of wear: a review of different theories.

Authors:  Mikael Sundfeldt; Lars V Carlsson; Carina B Johansson; Peter Thomsen; Christina Gretzer
Journal:  Acta Orthop       Date:  2006-04       Impact factor: 3.717

Review 2.  [Wear particles: key to aseptic prosthetic loosening?].

Authors:  M Otto; J Kriegsmann; T Gehrke; S Bertz
Journal:  Pathologe       Date:  2006-11       Impact factor: 1.011

3.  Effect of zoledronate on bone quality in the treatment of aseptic loosening of hip arthroplasty in the dog.

Authors:  L M Wise; S D Waldman; M Kasra; R Cheung; A Binnington; R A Kandel; L M White; M D Grynpas
Journal:  Calcif Tissue Int       Date:  2005-12-05       Impact factor: 4.333

4.  Quantitative small-animal surrogate to evaluate drug efficacy in preventing wear debris-induced osteolysis.

Authors:  E M Schwarz; E B Benz; A P Lu; J J Goater; A V Mollano; R N Rosier; J E Puzas; R J Okeefe
Journal:  J Orthop Res       Date:  2000-11       Impact factor: 3.494

5.  Effects of alendronate on particle-induced osteolysis in a rat model.

Authors:  Peter J Millett; Matthew J Allen; Mathias P G Bostrom
Journal:  J Bone Joint Surg Am       Date:  2002-02       Impact factor: 5.284

6.  Osteopontin deficiency impairs wear debris-induced osteolysis via regulation of cytokine secretion from murine macrophages.

Authors:  Sadanori Shimizu; Naoki Okuda; Norihiko Kato; Susan R Rittling; Atsushi Okawa; Kenichi Shinomiya; Takeshi Muneta; David T Denhardt; Masaki Noda; Kunikazu Tsuji; Yoshinori Asou
Journal:  Arthritis Rheum       Date:  2010-05

7.  The nitrogen-containing bisphosphonate, zoledronic acid, increases mineralisation of human bone-derived cells in vitro.

Authors:  Beiqing Pan; Luen Bik To; Amanda N Farrugia; David M Findlay; Jonathan Green; Stan Gronthos; Andreas Evdokiou; Kevin Lynch; Gerald J Atkins; Andrew C W Zannettino
Journal:  Bone       Date:  2004-01       Impact factor: 4.398

8.  The basic science of periprosthetic osteolysis.

Authors:  Stuart B Goodman; Emmanuel Gibon; Zhenyu Yao
Journal:  Instr Course Lect       Date:  2013

9.  Osteoblast proliferation and maturation by bisphosphonates.

Authors:  Gun-Il Im; Sheeraz A Qureshi; Jennifer Kenney; Harry E Rubash; Arun S Shanbhag
Journal:  Biomaterials       Date:  2004-08       Impact factor: 12.479

10.  Aminobisphosphonates cause osteoblast apoptosis and inhibit bone nodule formation in vitro.

Authors:  Aymen I Idris; Javier Rojas; Iain R Greig; Rob J Van't Hof; Stuart H Ralston
Journal:  Calcif Tissue Int       Date:  2008-02-08       Impact factor: 4.333

View more
  2 in total

1.  Additive Effect of Parathyroid Hormone and Zoledronate Acid on Prevention Particle Wears-Induced Implant Loosening by Promoting Periprosthetic Bone Architecture and Strength in an Ovariectomized Rat Model.

Authors:  Chenhe Zhou; Yangxin Wang; Jiahong Meng; Minjun Yao; Huikang Xu; Cong Wang; Fanggang Bi; Hanxiao Zhu; Guang Yang; Mingmin Shi; Shigui Yan; Haobo Wu
Journal:  Front Endocrinol (Lausanne)       Date:  2022-04-25       Impact factor: 6.055

2.  Piperlongumine Inhibits Titanium Particles-Induced Osteolysis, Osteoclast Formation, and RANKL-Induced Signaling Pathways.

Authors:  Xuan Liu; Li Diao; Yudie Zhang; Xue Yang; Junnan Zhou; Yuhang Mao; Xiaotian Shi; Fuli Zhao; Mei Liu
Journal:  Int J Mol Sci       Date:  2022-03-05       Impact factor: 5.923

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.